Abstract
One of the most important activities for completing a budget-impact analysis is understanding the population dynamics in order to estimate the size of the population eligible for the new drug. Determining those who are eligible for the new drug in the jurisdiction(s) of interest is a key determinant of the changes in costs and outcomes that may occur from the budget holder’s perspective. The credibility of the analysis will depend on the model correctly identifying those eligible for the new drug based on the treatment pathway in each jurisdiction. In this chapter, we present methods for estimating the size of the eligible incident and prevalent populations, including changes in the size and condition severity mix of these populations over the analysis time horizon. Issues around patient subgroups and catch-up are also presented.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsNotes
- 1.
In this chapter, we make the simplifying assumption that the budget-impact analysis is based on the introduction of a new drug to the current mix of drugs for treatment of a condition. Changes in our recommended approaches to estimate the budget impacts of other types of health-care interventions (i.e., vaccines, diagnostics, surgery, and devices) are discussed in Chap. 13.
References
Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The Burden of Obstructive Lung Disease (BOLD) initiative. Int J Tuberc Lung Dis. 2008;12(7):703–8.
Carlton BG, Lucas DO, Ellis EF, Conboy-Ellis K, Shoheiber O, Stempel DA. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. J Asthma. 2005;42(7):529–35.
Carter M, Moser K, Kelly S. Office of National Statistics. Health of older people: disease prevalence, prescription and referral rates, England and Wales 1996. Health Stat Q. 1999;4:9–15.
Centers for Disease Control and Prevention (CDC). Hepatitis C FAQs for health professionals. 2016. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 28 Jul 2016.
Crighton EJ, Ragetlie R, Luo J, To T, Gershon A. A spatial analysis of COPD prevalence, incidence, mortality and health service use in Ontario. Health Rep. 2015;26(3):10–8.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292. doi:10.1161/01.cir.0000441139.02102.80.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38. doi:10.1056/NEJMoa0909883.
Lee TA, Chang CL, Stephenson JJ, Sajjan SG, Maiese EM, Everett S, et al. Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Curr Med Res Opin. 2010;26(12):2851–60. doi:10.1185/03007995.2010.531255.
Maggioni AP, Anand I, Gottleib SO, Latini R, Tognoni G, Cohn JN. Val_HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414–21.
Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National surveillance of asthma: United States, 2001-2010. Vital Health Stat. 2012;3(35):1–58.
Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19(10):2596–606.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700–22.
US Census Bureau, Population Division. Annual estimates of the resident population by single year of age and sex for the United States, states, and Puerto Rico Commonwealth: April 1, 2010 to July 1, 2012. 2013. http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk. Accessed 30 Oct 2013.
US Census Bureau. US and world population clock. 2014. http://www.census.gov/popclock/. Accessed 28 Jul 2016.
World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections – 2008. 2012. http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf?ua=1. Accessed 15 Sep 2015.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Earnshaw, S., Mauskopf, J. (2017). Estimating the Diagnosed, Treated, and Eligible Population. In: Budget-Impact Analysis of Health Care Interventions. Adis, Cham. https://doi.org/10.1007/978-3-319-50482-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-50482-7_3
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-50480-3
Online ISBN: 978-3-319-50482-7
eBook Packages: MedicineMedicine (R0)